Everest Group Declares ‘The Age of Decentralized Clinical Trials Has Begun’
Everest Group
MARCH 29, 2023
Everest Group predicts that the adoption of DCTs by pharmaceutical companies will rapidly accelerate as early adopters praise the approach for putting patient experience at the forefront. When asked to name the biggest benefit of DCTs, two out of three of those buyers interviewed (67%) cited “improved patient enrollment and retention rates.”
52 
Let's personalize your content